<DOC>
	<DOCNO>NCT02473939</DOCNO>
	<brief_summary>The purpose study Evaluate safety , tolerability , pharmacodynamics pharmacokinetics single inhaled dos VR942 healthy subject ( part 1 ) repeat dos mild asthmatic ( part 2 ) .</brief_summary>
	<brief_title>An Evaluation VR942 Healthy Volunteers Patients With Mild Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion Criteria Part I &amp; 2 : Male female subject . Female subject nonchildbearing potential Weigh least 50 kg , body mass index 18.031.0 Peak inspiratory flow ( PIF ) least 60 L/min least 2 sec Forced expiratory volume 1 sec ( FEV1 ) /forced vital capacity ( FVC ) ratio least 0.7 screen visit Willingness give write consent participate read information consent form Willingness give write consent data enter The Over volunteering Prevention System . Additional inclusion criterion Part 1 : Healthy subject FEV1 FVC least 80 % predict value screen visit Additional inclusion criterion Part 2 : Patients document clinical history mild bronchial asthma ( mild define GINA guidelines1 ) least 6 month screen visit Patient FEV1 FVC least 70 % predict value screen visit Exclusion Criteria Part 1 &amp; 2 : Clinically relevant abnormal history , physical finding , ECG , laboratory value pretrial screen assessment Presence acute chronic illness history chronic illness sufficient invalidate subject 's participation trial make unnecessarily hazardous ( exclude mild asthma Part 2 ) Impaired endocrine , thyroid , hepatic , respiratory ( exclude mild asthma Part 2 ) renal function , diabetes mellitus , coronary heart disease , cancer , history psychotic mental illness Respiratory tract infection within 4 week screen visit History surgery medical intervention , plan surgery medical intervention Presence history severe adverse reaction drug , sensitivity component trial medication Use prescription overthecounter medicine , exception acetaminophen ( paracetamol ) , 7 day first dose trial medication . For Part 2 , inhale shortacting ß2 agonist , ICS ( stable dose least 2 week document use ≥80 % compliance screen Day 1 ) permit Participation another clinical trial new chemical entity , new device , prescription medicine within 3 month dose , participation within 5 halflives receive experimental drug ( whichever longer ) Presence history drug alcohol abuse Evidence drug abuse urine testing , positive test alcohol Current smoker ; exsmokers ( ) give less 1 year ago , ( b ) history 10 packyears Blood pressure heart rate screen examination outside range 90140 mm Hg systolic , 4090 mm Hg diastolic ; heart rate 40100 beats/min . Loss 400 mL blood , eg blood donor , donation blood product , 3 month trial Positive test hepatitis B , hepatitis C , HIV Possibility subject cooperate requirement protocol , include effective use DPI Additional exclusion criterion Part 2 : Lifethreatening asthmatic episode past Asthmatic episode respiratory tract infection require steroid treatment past 3 month Use follow medicine within specified time screening : Longacting ß2 agonist ; At time screen Anti IgE therapy ; 6 month Inhaled corticosteroid ( &gt; 500 µg per day beclometasone dipropionate ( BDP ) equivalent ) ; 8 week Oral injectable steroid ; 8 week Intranasal topical steroid ; 4 week Leukotriene antagonist ; 2 week Xanthines ( exclude caffeine ) , anticholinergic , cromoglycates ; 1 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>